carbamates has been researched along with Complication, Postoperative in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease." | 7.91 | Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection. ( Akarca, US; Danış, N; Ersöz, G; Günşar, F; Karasu, Z; Özkahya, M; Toz, H; Turan, İ; Ünal, N; Yılmaz, M, 2019) |
| " Clinical and laboratory adverse events (AEs) were recorded from baseline to FU12." | 5.46 | Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. ( Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M, 2017) |
| "The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease." | 3.91 | Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection. ( Akarca, US; Danış, N; Ersöz, G; Günşar, F; Karasu, Z; Özkahya, M; Toz, H; Turan, İ; Ünal, N; Yılmaz, M, 2019) |
| "Viral recurrence occurs in all patients with detectable serum HCV RNA at the time of transplantation leading to cirrhosis in 20-30% of patients within 5 years." | 2.52 | Management of post transplant hepatitis C in the direct antiviral agents era. ( Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D, 2015) |
| "Liver fibrosis was graded with the use of biopsies taken <12 months before treatment and stratified as early (0-1) or moderate to advanced (2-4) according to the Metavir score." | 1.48 | Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study. ( Bandeira de Mello Brandao, A; Costabeber, AM; Cracco Cantisani, GP; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Medeiros Fleck, A; Meine, MH; Mucenic, M; Sacco, FKF; Soares Schlindwein, E; Zanotelli, ML, 2018) |
| " Clinical and laboratory adverse events (AEs) were recorded from baseline to FU12." | 1.46 | Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. ( Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M, 2017) |
| " DCV-based DAA treatment is efficacious and safe in patients with HCV infection after LT." | 1.46 | Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. ( Bañares, R; Casafont, F; Castellote, J; Castells, L; Cuervas-Mons, V; Espinosa, MD; Fernández, I; García-Gonzalez, M; González, A; González-Diéguez, L; Herrero, JI; Llaneras, J; Londoño, MC; Lorente, S; Molina Pérez, E; Montero Alvarez, JL; Narváez, I; Otero, A; Pascasio, JM; Pascual, S; Pons, JA; Prieto, M; Salcedo, M; Sánchez-Antolín, G; Sousa, JM; Testillano, M; Vinaixa, C, 2017) |
| "DAA are highly effective in the treatment of hepatitis C in KTRs with good tolerance in general, making it possible to solve the problem and have a good chance to improve the prognosis in our transplantation patients." | 1.43 | Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study. ( Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S, 2016) |
| " Importantly, adjustments to the immunosuppressant dosage were not required." | 1.42 | Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant. ( Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Papadopoulos-Köhn, A; Paul, A; Timm, J; Walker, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Danış, N | 1 |
| Toz, H | 1 |
| Ünal, N | 1 |
| Yılmaz, M | 1 |
| Turan, İ | 1 |
| Günşar, F | 1 |
| Karasu, Z | 1 |
| Ersöz, G | 1 |
| Özkahya, M | 1 |
| Akarca, US | 1 |
| Tronina, O | 1 |
| Durlik, M | 1 |
| Wawrzynowicz-Syczewska, M | 1 |
| Buivydiene, A | 1 |
| Katzarov, K | 1 |
| Kupcinskas, L | 1 |
| Tolmane, I | 1 |
| Karpińska, E | 1 |
| Pisula, A | 1 |
| Karwowska, KM | 1 |
| Bolewska, B | 1 |
| Jabłkowski, M | 1 |
| Rostkowska, K | 1 |
| Jakutiene, J | 1 |
| Simonova, M | 1 |
| Flisiak, R | 1 |
| Salcedo, M | 1 |
| Prieto, M | 1 |
| Castells, L | 1 |
| Pascasio, JM | 1 |
| Montero Alvarez, JL | 1 |
| Fernández, I | 1 |
| Sánchez-Antolín, G | 1 |
| González-Diéguez, L | 1 |
| García-Gonzalez, M | 1 |
| Otero, A | 1 |
| Lorente, S | 1 |
| Espinosa, MD | 1 |
| Testillano, M | 1 |
| González, A | 1 |
| Castellote, J | 1 |
| Casafont, F | 1 |
| Londoño, MC | 1 |
| Pons, JA | 1 |
| Molina Pérez, E | 1 |
| Cuervas-Mons, V | 1 |
| Pascual, S | 1 |
| Herrero, JI | 1 |
| Narváez, I | 1 |
| Vinaixa, C | 1 |
| Llaneras, J | 1 |
| Sousa, JM | 1 |
| Bañares, R | 1 |
| Ikegami, T | 1 |
| Ueda, Y | 2 |
| Akamatsu, N | 1 |
| Ishiyama, K | 1 |
| Goto, R | 1 |
| Soyama, A | 1 |
| Kuramitsu, K | 1 |
| Honda, M | 1 |
| Shinoda, M | 1 |
| Yoshizumi, T | 1 |
| Okajima, H | 1 |
| Kitagawa, Y | 1 |
| Inomata, Y | 1 |
| Ku, Y | 1 |
| Eguchi, S | 1 |
| Taketomi, A | 1 |
| Ohdan, H | 1 |
| Kokudo, N | 1 |
| Shimada, M | 1 |
| Yanaga, K | 1 |
| Furukawa, H | 1 |
| Uemoto, S | 2 |
| Maehara, Y | 1 |
| Mucenic, M | 1 |
| Bandeira de Mello Brandao, A | 1 |
| Marroni, CA | 1 |
| Medeiros Fleck, A | 1 |
| Zanotelli, ML | 1 |
| Kiss, G | 1 |
| Meine, MH | 1 |
| Leipnitz, I | 1 |
| Soares Schlindwein, E | 1 |
| Martini, J | 1 |
| Costabeber, AM | 1 |
| Sacco, FKF | 1 |
| Cracco Cantisani, GP | 1 |
| Vanhoutte, C | 1 |
| Goossens, A | 1 |
| Gilissen, L | 1 |
| Huygens, S | 1 |
| Vital-Durand, D | 1 |
| Dendooven, E | 1 |
| Aerts, O | 1 |
| Coilly, A | 1 |
| Roche, B | 1 |
| Duclos-Vallée, JC | 1 |
| Samuel, D | 1 |
| Herzer, K | 1 |
| Papadopoulos-Köhn, A | 1 |
| Walker, A | 1 |
| Achterfeld, A | 1 |
| Paul, A | 1 |
| Canbay, A | 1 |
| Timm, J | 1 |
| Gerken, G | 1 |
| Gentil, MA | 1 |
| González-Corvillo, C | 1 |
| Perelló, M | 1 |
| Zarraga, S | 1 |
| Jiménez-Martín, C | 1 |
| Lauzurica, LR | 1 |
| Alonso, A | 1 |
| Franco, A | 1 |
| Hernández-Marrero, D | 1 |
| Sánchez-Fructuoso, A | 1 |
| Dautzenberg, PL | 1 |
| Wouters, CJ | 1 |
| Oudejans, I | 1 |
| Samson, MM | 1 |
| KINIFFO, V | 1 |
| Speck, B | 1 |
| Wild, A | 1 |
| Walsh, J | 1 |
| Bonnar, J | 1 |
1 review available for carbamates and Complication, Postoperative
| Article | Year |
|---|---|
Management of post transplant hepatitis C in the direct antiviral agents era.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Li | 2015 |
1 trial available for carbamates and Complication, Postoperative
| Article | Year |
|---|---|
[Clinical testing of the gastrotherapeutical drug Alutan].
Topics: Acidosis; Carbamates; Clinical Trials as Topic; Female; Gastritis; Gastrointestinal Agents; Humans; | 1967 |
12 other studies available for carbamates and Complication, Postoperative
| Article | Year |
|---|---|
Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Female; | 2019 |
Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, C | 2017 |
Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Female; Hepatitis C; Humans; Imidazole | 2017 |
Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience.
Topics: Adult; Aged; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studie | 2017 |
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepati | 2018 |
Concomitant contact-allergic reactions to iodopropynyl butylcarbamate and iodine.
Topics: Adult; Aged; Anti-Infective Agents, Local; Carbamates; Dermatitis, Allergic Contact; Dermatitis, Occ | 2019 |
Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus | 2015 |
Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Intera | 2016 |
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; H | 2016 |
Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease.
Topics: Aged; Aortic Valve Insufficiency; Carbamates; Cholinesterase Inhibitors; Colitis, Ulcerative; Deliri | 2003 |
[INFLUENCE OF AN ORTHONEUROTIC AGENT DURING SURGICAL EDEMA].
Topics: Carbamates; Dupuytren Contracture; Edema; Finger Injuries; Hand Injuries; Humans; Joint Diseases; Me | 1964 |
Distigmine bromide (Ubretid) for the prevention of urinary retention after vaginal hysterectomy.
Topics: Adult; Carbamates; Cholinesterase Inhibitors; Female; Humans; Hysterectomy; Injections, Intramuscula | 1972 |